Dec 19, 2019
Karius Test Demonstrates Ability To Detect Bloodstream Infections In Pediatric Patients With Cancer Before Symptoms Develop
Dec 13, 2019
Bay Area Lyme Foundation Highlights 2019 Progress toward Diagnosing, Treating and Preventing Lyme Disease
Dec 05, 2019
Nozin Nasal Sanitizer Programs Reduce MRSA Infections, Lower Healthcare Costs Say Hospital Clinicians
Nov 25, 2019
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Nov 20, 2019
IGeneX Introduces Cost-Effective Tests for Lyme Disease and TBRF
Nov 14, 2019
Magnolia Medical Announces Partnership with Cardinal Health
Nov 12, 2019
EU-Funding: Micreos Awarded EUR2.5 Million for Breakthrough for Skin Problems Including Acne and Eczema
Nov 11, 2019
TenNor Therapeutics Reported Phase II Top-Line Results for TNP-2092
Nov 01, 2019
Center for Lyme Action Applauds Senate Health Committee Advancing TICK Act
Oct 31, 2019
Armata Pharmaceuticals Issues Letter to Shareholders
Oct 23, 2019
Global Nontuberculous Mycobacterial Infections Pipeline Report 2019: Therapeutic Candidates in Discovery and Preclinical, Phase 1, Phase 2, and Phase 3 Stage
Oct 23, 2019
Biomica to Collaborate With Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic Resistant Bacteria
Oct 22, 2019
Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model
Oct 15, 2019
New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
Oct 14, 2019
Scientists from NUST MISIS Create a Material for Implants Which Destroys up to 98% of Bacteria
Oct 11, 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Oct 08, 2019
New York State Grants Approval for IGeneX's Newly Developed Tick-Borne Relapsing Fever (TBRF) ImmunoBlot Tests
Oct 01, 2019
Luminex Receives FDA 510(k) Clearance for the ARIES® MRSA Assay
Sep 12, 2019
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
Sep 03, 2019
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa